CTX is commercializing a peptide-based skin-permeation platform technology that carries large molecules into human skin.  This makes possible topical delivery of medications that today must be delivered orally or by injection (or not at all).  Our lead formulation of topical cyclosporine for mild-to-moderate plaque psoriasis is in pre-clinical development and shows promise as a possible disease-modifying medication for the tens of millions of patients currently using corticosteroids, phototherapy, vitamin therapy or coal tar.

Our platform technology can also improve skincare and haircare products and we are in discussion with major consumer products companies for product licensing.